Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc Wheeler J; McHale M; Jackson V; Penny MAntivir Ther 2007[]; 12 (2): 233-45The proliferation of published gene association studies of the CCR5delta32 mutation is of relevance to drug development of a CCR5 antagonist for HIV, in highlighting potential safety concerns. We conducted an initial review of all non-HIV gene association studies of CCR5-delta32, followed by detailed meta-analyses in the three disease areas most commonly reported. Our review indicated no consistent evidence of increased risk of susceptibility to hepatitis C virus infection or multiple sclerosis among individuals with CCR5-delta32 mutation, and suggested treatment with a CCR5 inhibitor is unlikely to have related adverse effects. There was, however, evidence to suggest rheumatoid arthritis as a potential therapeutic target for a CCR5 antagonist. Clinical evidence would be required to confirm these findings.|*CCR5 Receptor Antagonists[MESH]|*Drug Design[MESH]|Adult[MESH]|Arthritis, Rheumatoid/drug therapy/genetics[MESH]|Cyclohexanes/*adverse effects[MESH]|Female[MESH]|Genotype[MESH]|HIV Fusion Inhibitors/*adverse effects[MESH]|HIV Infections/drug therapy/genetics[MESH]|Hepatitis C/chemically induced/genetics[MESH]|Humans[MESH]|Male[MESH]|Maraviroc[MESH]|Multiple Sclerosis/chemically induced/genetics[MESH]|Mutation[MESH]|Pharmacogenetics/*methods[MESH]|Receptors, CCR5/*genetics/metabolism[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Triazoles/*adverse effects[MESH] |